Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Economic Profit

Merck & Co. Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance from 2021 to 2025 is characterized by significant volatility in operating profitability and a substantial expansion of the capital base, resulting in a fluctuating economic profit profile. A severe contraction occurred in 2023, followed by a robust recovery and subsequent growth in value creation through 2025.

Net Operating Profit After Taxes (NOPAT)
Operating profitability demonstrated a stable upward trajectory between 2021 and 2022, before experiencing a sharp reversal in 2023, where NOPAT fell to negative 714 million US$. This downturn was followed by a significant recovery in 2024, with profit rising to 16,744 million US$, and further growth to 17,864 million US$ by 2025.
Invested Capital and Cost of Capital
Invested capital remained relatively stable between 2021 and 2023, with a slight dip in 2023 to 69,966 million US$. However, a period of aggressive capital expansion followed, with invested capital increasing to 79,426 million US$ in 2024 and reaching 97,963 million US$ by 2025. Concurrently, the cost of capital remained narrow in range, peaking at 7.85% in 2023 and stabilizing around 7.68% by 2025.
Economic Profit and Value Creation
Economic profit mirrored the volatility of NOPAT, shifting from a positive position of 8,113 million US$ in 2021 to a substantial deficit of 6,210 million US$ in 2023, indicating a period of value destruction. A strong rebound occurred in 2024, yielding a peak economic profit of 10,662 million US$. Despite the continued increase in invested capital in 2025, economic profit remained strong at 10,338 million US$, though it experienced a slight marginal decline from the 2024 peak.

The overall trend indicates that while the cost of capital remained constant, the company's ability to generate economic value became heavily dependent on the recovery of NOPAT. The significant increase in invested capital toward the end of the period suggests a strategic expansion, which the company successfully leveraged to maintain a high level of economic profit despite the increased capital charge.


Net Operating Profit after Taxes (NOPAT)

Merck & Co. Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net income attributable to Merck & Co., Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for doubtful accounts2
Increase (decrease) in LIFO reserve3
Increase (decrease) in restructuring reserves4
Increase (decrease) in equity equivalents5
Interest expense
Interest expense, operating lease liability6
Adjusted interest expense
Tax benefit of interest expense7
Adjusted interest expense, after taxes8
(Gain) loss on marketable securities
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income9
Investment income, after taxes10
(Income) loss from discontinued operations, net of tax11
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for doubtful accounts.

3 Addition of increase (decrease) in LIFO reserve. See details »

4 Addition of increase (decrease) in restructuring reserves.

5 Addition of increase (decrease) in equity equivalents to net income attributable to Merck & Co., Inc..

6 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

7 2025 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

8 Addition of after taxes interest expense to net income attributable to Merck & Co., Inc..

9 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

10 Elimination of after taxes investment income.

11 Elimination of discontinued operations.


Net income attributable to Merck & Co., Inc. and Net Operating Profit After Taxes (NOPAT) demonstrate distinct performance patterns over the five-year period. While net income generally exhibits an upward trajectory, NOPAT reveals a more volatile performance, including a significant decline in 2023.

Overall Trend - Net Income
Net income attributable to Merck & Co., Inc. increased from US$13,049 million in 2021 to US$14,519 million in 2022. A substantial decrease was observed in 2023, falling to US$365 million, before recovering significantly to US$17,117 million in 2024 and further increasing to US$18,254 million in 2025. This indicates a generally positive trend with a notable disruption in 2023.
Overall Trend - NOPAT
NOPAT followed a similar pattern to net income through 2022, increasing from US$13,349 million in 2021 to US$14,154 million in 2022. However, NOPAT experienced a dramatic decline in 2023, resulting in a negative value of US$-714 million. Subsequent years showed a strong recovery, with NOPAT reaching US$16,744 million in 2024 and US$17,864 million in 2025.
Comparison of Net Income and NOPAT
While both metrics generally move in the same direction, the magnitude of change differs. The decline in 2023 was far more pronounced for NOPAT than for net income. This suggests that factors impacting operating profitability, rather than solely net income, were the primary drivers of the 2023 downturn. The recovery in 2024 and 2025 was also substantial for NOPAT, indicating improved operational performance. The difference between net income and NOPAT suggests the presence of non-operating items or tax effects influencing net income.
NOPAT Volatility
The significant fluctuation in NOPAT, particularly the negative value in 2023, warrants further investigation. This volatility could be attributed to changes in operating expenses, revenue recognition, or other factors affecting the core profitability of the business. The subsequent recovery suggests these issues were addressed or were temporary in nature.

Cash Operating Taxes

Merck & Co. Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Taxes on income from continuing operations
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The reported taxes on income from continuing operations exhibited fluctuations over the five-year period. Initial values increased from 2021 to 2022, followed by a decrease in 2023, and then a substantial rise in 2024 and 2025, remaining relatively stable between those final two years. However, a more pronounced trend is observed in cash operating taxes.

Cash Operating Taxes Trend
Cash operating taxes demonstrate a significant increase from 2021 to 2022, nearly doubling from US$1,553 million to US$3,760 million. This increase is followed by a moderate decline in 2023 to US$3,497 million. Subsequent years, 2024 and 2025, show continued growth, reaching US$4,246 million and US$4,597 million respectively. The pattern suggests a generally increasing tax burden as measured by cash outflows.

The divergence between taxes on income from continuing operations and cash operating taxes is notable. While income taxes fluctuated, cash operating taxes consistently increased over the period, albeit with a slight dip in 2023. This difference could be attributable to timing differences between reported income tax expense and actual cash payments, such as deferred tax assets or liabilities, or changes in tax credits utilized. The substantial increase in cash operating taxes from 2021 to 2022 warrants further investigation to understand the underlying drivers, potentially including changes in tax laws, profitability, or the utilization of tax loss carryforwards.

Comparative Analysis
The difference between the two tax measures widened considerably in 2022 and remained elevated through 2025. In 2021, the difference was US$32 million. By 2022, this difference grew to US$1,842 million. While the gap narrowed somewhat in 2023 (US$1,985 million), it expanded again in 2024 (US$1,443 million) and 2025 (US$1,793 million). This sustained difference suggests a significant impact on free cash flow and should be considered when evaluating economic value added.

The consistent upward trend in cash operating taxes, particularly when contrasted with the more volatile reported income taxes, indicates a growing cash commitment to tax obligations. This trend should be monitored closely as it directly impacts available cash for reinvestment, debt reduction, or shareholder returns.


Invested Capital

Merck & Co. Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Loans payable and current portion of long-term debt
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Total Merck & Co., Inc. stockholders’ equity
Net deferred tax (assets) liabilities2
Allowance for doubtful accounts3
LIFO reserve4
Restructuring reserves5
Equity equivalents6
Accumulated other comprehensive (income) loss, net of tax7
Noncontrolling interests
Adjusted total Merck & Co., Inc. stockholders’ equity
Construction in progress8
Investments in debt and publicly traded equity securities9
Invested capital

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of LIFO reserve. See details »

5 Addition of restructuring reserves.

6 Addition of equity equivalents to total Merck & Co., Inc. stockholders’ equity.

7 Removal of accumulated other comprehensive income.

8 Subtraction of construction in progress.

9 Subtraction of investments in debt and publicly traded equity securities.


The invested capital of the company exhibited fluctuations over the five-year period. Total reported debt & leases and total stockholders’ equity both contribute to the calculation of invested capital, and their individual trends influence the overall invested capital figure.

Invested Capital Trend
Invested capital increased from US$70,735 million in 2021 to US$73,942 million in 2022, representing a growth of approximately 4.5%. A subsequent decrease was observed in 2023, with invested capital falling to US$69,966 million. This was followed by a more substantial increase in 2024, reaching US$79,426 million, and continued growth in 2025 to US$97,963 million. The most significant increase occurred between 2024 and 2025.
Debt & Leases
Total reported debt & leases decreased from US$34,631 million in 2021 to US$31,985 million in 2022. An increase was then noted in 2023, reaching US$36,268 million, and continued into 2024 with a value of US$38,270 million. A considerable rise occurred in 2025, with debt & leases reaching US$50,534 million. This suggests a shift towards increased reliance on debt financing in the latter part of the period.
Stockholders’ Equity
Total stockholders’ equity increased significantly from US$38,184 million in 2021 to US$45,991 million in 2022. A decrease was observed in 2023, with equity falling to US$37,581 million. Equity then rebounded in 2024 to US$46,313 million and continued to grow in 2025, reaching US$52,606 million. The fluctuations in equity likely reflect retained earnings, share issuances, and share repurchases.

The combined effect of these trends in debt and equity resulted in the overall pattern observed in invested capital. The substantial increase in invested capital between 2024 and 2025 appears to be driven by a combination of increased debt and equity, with debt contributing a larger proportion of the growth.


Cost of Capital

Merck & Co. Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Loans payable and long-term debt, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2025-12-31).

1 US$ in millions

2 Equity. See details »

3 Loans payable and long-term debt, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Loans payable and long-term debt, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Loans payable and long-term debt, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Loans payable and long-term debt, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Loans payable and long-term debt, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Loans payable and long-term debt, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Loans payable and long-term debt, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Loans payable and long-term debt, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Loans payable and long-term debt, including current portion. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Merck & Co. Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The analysis of economic value added indicates a period of significant volatility followed by a recovery and an expansion of the capital base. While value creation remained positive for the majority of the period, a notable contraction occurred in 2023 before rebounding to higher levels in subsequent years.

Economic Profit Trends
Economic profit showed slight growth between 2021 and 2022, rising from 8,113 million US$ to 8,360 million US$. A sharp reversal was observed in 2023, where profit fell to negative 6,210 million US$. This downturn was followed by a strong recovery in 2024, with profit reaching a period peak of 10,662 million US$, before stabilizing at 10,338 million US$ in 2025.
Invested Capital Growth
Invested capital demonstrated a general upward trajectory, increasing from 70,735 million US$ in 2021 to 97,963 million US$ by 2025. A temporary decrease was recorded in 2023, coinciding with the decline in economic profit. However, capital deployment accelerated significantly in the final two years, with a particularly substantial increase observed between 2024 and 2025.
Economic Spread Ratio Performance
The economic spread ratio closely mirrored the volatility of economic profit, maintaining a stable range between 11.31% and 11.47% during 2021 and 2022. A significant collapse occurred in 2023, with the ratio dropping to -8.88%, signifying that returns on invested capital fell below the cost of capital. Efficiency recovered sharply in 2024 to a peak of 13.42%. In 2025, the ratio declined to 10.55%, suggesting that the rapid expansion of the invested capital base outpaced the growth in economic profit.

Economic Profit Margin

Merck & Co. Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Economic profit1
Sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 Economic profit. See details »

2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Sales
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial performance between 2021 and 2025 is characterized by consistent revenue growth contrasted with significant volatility in economic profit and its associated margin. While sales exhibited a steady upward trajectory throughout the period, the economic value generated experienced a severe contraction in 2023 before recovering to levels exceeding the initial 2021 baseline.

Revenue Growth Trends
Sales increased consistently every year, rising from 48,704 million USD in 2021 to 65,011 million USD by 2025. This represents a steady expansion of the top line, indicating a sustained increase in market reach or pricing power over the five-year window.
Economic Profit Fluctuations
Economic profit demonstrated a non-linear trend. After a stable start in 2021 and 2022, where profit ranged between 8,113 million USD and 8,360 million USD, a substantial decline occurred in 2023, resulting in a negative economic profit of 6,210 million USD. A robust recovery followed in 2024, with profit peaking at 10,662 million USD, before slightly moderating to 10,338 million USD in 2025.
Economic Profit Margin Analysis
The economic profit margin mirrored the volatility of the absolute profit figures. The margin declined from 16.66% in 2021 to 14.10% in 2022, followed by a sharp collapse to -10.33% in 2023. This negative margin indicates that during 2023, the company failed to generate returns above its cost of capital despite achieving record sales. The margin returned to a strong position in 2024 at 16.62%, nearly matching 2021 levels, and settled at 15.90% in 2025.

The divergence between the constant growth in sales and the extreme fluctuation in economic profit suggests that external shocks or significant internal capital expenditures occurred in 2023. The rapid return to positive economic profit margins in 2024 indicates a successful restoration of value creation efficiency relative to the capital employed.